Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2010
-
By James DeGiulio — On June 4, in an effort to address the application backlog and its alleged negative impact on innovation, the U.S. Patent and Trademark Office issued a notice concerning an Enhanced Examination Timing Control Initiative (75 Fed. Reg. 31763). The initiative would, among other provisions, create three examination tracks: an accelerated examination…
-
By Donald Zuhn — Last month, the U.S. Patent and Trademark Office announced a change in the way registered practitioners can show authorization to participate in an examiner interview. Under the old procedure, practitioners were required to file a power of attorney or authorization to act in a representative capacity in order to participate in…
-
By Kevin E. Noonan — The staid Financial Times (London) has an article today on the gene patenting debate, and while there are things to criticize in it, the article (perhaps predictably) takes a carefully measured, dispassionate (and welcome) tone ("Who steals the gene from off the common"; free registration required). The paper's conservative bona…
-
By Donald Zuhn — On Thursday, the U.S. Court of Appeals for the Federal Circuit issued an Order in Eli Lilly & Co. v. Actavis Elizabeth LLC, continuing a temporary injunction that had been granted by the District Court for the District of New Jersey one week earlier. Lilly moved for the injunction, which prohibits…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company v. Sandoz, Inc.1:10-cv-01057; filed August 23, 2010 in the Southern District of Indiana Infringement of U.S. Patent No. 5,464,826 ("Method of Treating Tumors in Mammals with 2',2'-difluoronucleosides," issued November 7, 1995)…
-
September 1-2, 2010 – 7th Annual Pharmaceutical Law Summer School (IBC Legal) – London, UK September 7-9, 2010 – BioPatent Design (Pharma IQ) – Munich, Germany September 8, 2010 – Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting – 10:00 am – 4:15 pm September 12-14, 2010 – 2010 Annual Meeting (Intellectual Property Owners Association) – Atlanta, GA…
-
The Center for Business Intelligence (CBI) will be holding its 3rd Annual Life Sciences Congress on Paragraph IV Disputes concerning Emerging Regulatory and Pre-Litigation Strategies for Prosecuting and Defending PIV Suits on October 18-19, 2010 in Alexandria, VA. The conference will offer presentations on the following topics: • Generic vs. generic suits;• FTC investigations and…
-
C5 (UK) will be holding its 19th Forum on Biotech Patenting on October 6-7, 2010 in London, England. Regulators, biotech practitioners, and experienced in-house counsel will provide information on: • The latest strategies for adapting one's patent practice to the EPO rule changes;• The EPO examiner's perspective on patenting biotechnological inventions;• Satisfying the requirements for…
-
By James DeGiulio — Mirapex Case Ends, Mylan Found to Infringe Boehringer Patent On August 18, Boehringer's long-running case against Mylan over the drug Mirapex came to a close after Mylan was found to infringe Boehringer's patent and an injunction was issued prohibiting Mylan from producing generic pramipexole dihydrochloride. In 2005, Boehringer brought suit against…
-
By Donald Zuhn — Scientific American has released its second annual examination of the ways in which governments, scientists, industry players, and life science stakeholders are advancing biotechnology innovation around the globe. The special edition of the consumer science magazine, entitled "Worldview: A Global Biotechnology Perspective," explores biotech's most compelling trends and developments worldwide. The…
Patent Docs 